We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+17.74%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$954M
AUM Growth
+$43.5M
Cap. Flow
-$47.3M
Cap. Flow %
-4.96%
Top 10 Hldgs %
75.65%
Holding
29
New
6
Increased
8
Reduced
7
Closed
5

Top Buys

Rank Stock Value
1
CORT icon
Corcept Therapeutics
CORT
+$45.4M
2
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$45.3M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$36.3M
4
GMED icon
Globus Medical
GMED
+$29.3M
5
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$20M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$84.9M
2
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$44.2M
3
MD icon
Pediatrix Medical
MD
+$44M
4
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$37M
5
AMAG
AMAG Pharmaceuticals
AMAG
+$35.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VCYT icon
26
Veracyte
VCYT
$4.45B
– –
-46,752
Closed -$362K
AMAG
27
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-1,026,902
Closed -$35.7M
MACK
28
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
– –
-1,152,543
Closed -$37M
ARIA
29
DELISTED
Ariad Pharmaceuticals Inc
ARIA
– –
-3,553,943
Closed -$44.2M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, Consonance Capital Management held 29 positions worth $954M, up 4.8% from $911M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Consonance Capital Management withdrew a net $47.3M in Q1 2017, closing 5 positions and reducing 7 holdings. Its most notable exit was Ariad Pharmaceuticals Inc, an estimated $44.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier.

Against the trend, Consonance Capital Management opened a new position in Corcept Therapeutics worth $56.7M.

  • Consonance Capital Management's largest Q1 2017 buy was Corcept Therapeutics: 5,169,640 shares worth $56.7M.
  • Consonance Capital Management added most to Globus Medical in Q1 2017, an estimated $29.3M increase.
  • Consonance Capital Management's biggest Q1 2017 reduction was Clovis Oncology, Inc., cutting an estimated $84.9M.
  • Consonance Capital Management fully exited Ariad Pharmaceuticals Inc in Q1 2017, selling an estimated $44.2M.
  • Consonance Capital Management's ten largest holdings make up 76% of its $954M portfolio in Q1 2017.
  • Consonance Capital Management opened 6 new positions and closed 5 in Q1 2017.
  • Consonance Capital Management's portfolio value rose 4.8% quarter-over-quarter to $954M.

Based on Consonance Capital Management's 13F filing for Q1 2017, filed 15 May 2017.